A A A

 

Wichtige Puklikationen seit 01.01.2007:

 

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.17747.

 

Pogge von Strandmann E, Reinartz S, Wager U, Müller R. Tumor- host cell interactions in ovarian cancer: Pathways to therapy failure.
Trends in Cancer, Vol. 3, Issue 2, p137–148

 

Sauer M, Schuldner M, Hoffmann N, Cetintas A, Reiners KS, Shatnyeva O, Hallek M, Hansen HP, Gasser S, von Strandmann EP.
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Oncogene 2017 Feb16;36(7):933-941

 

Vyas M, Müller R, Pogge von Strandmann E.
Antigen Loss Variants: Catching Hold of Escaping Foes.
Front Immunol 2017 Feb 24;8:175

 

Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Müller R.
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.
Front Oncol 2017 Feb 22; 7:24

 

Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, von Strandmann EP.
Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells.
Haematologica 2017 Mar;102(3):e100-e103

 

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
Oncoimmunology 2016 Apr 25;6(1):e1137418

 

Daßler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert R, Tüting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C.
RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Oncoimmunology. 2016 Aug 19;5(10):e1219827

 

Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E.
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.
Oncoimmunology 2016 Jul 15;5(9):e1211220


Strandmann EP, Müller R.
Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer.
Trends Mol Med 2016 Sep;22(9):741-3

 

Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E.
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Oncotarget 2016 May 24;7(21):30523-35

 

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.
Oncoimmunology 2015 Aug 12;5(4):e1071008.

 

Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A.
A phase 1 study of the bispecific anti-CD30/CD16A antibody contruct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Blood 2015 Jun 25;125(26):4024-31

 

Shatnyeva OM, Hansen HP, Reiners KS, Sauer M, Vyas M, von Strandmann EP.
DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.
Front Genet 2015 Feb 4;6:11

 

Thomsen H, da Silva Filho MI, Försti A, Fuchs M, Ponader S, von Strandmann EP, Eisele L, Herms S, Hofmann P, Sundquist J, Engert A, Hemminki K.
Heritability estimates on Hodgkin’s lymphoma: a genomic- versus population-based approach.
Eur J Hum Genet 2015 Jun;23(6):824-30

 

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, Cerwenka A.
Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Cancer Res 2014 Jul 1;74(13):3429-40

 

Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Dürkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, Pogge von Strandmann E.
Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin’s lymphoma.
J Pathol 2014 Mar;232(4):405-14

 

Reiners KS, Dassler J, Coch C, Pogge von Strandmann E.
Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell  Plasticity.
Front Immunol 2014 Mar 7;5:91

 

Vyas M, Koehl U, Hallek M, von Strandmann EP.
Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.
Trends Mol Med 2014 Feb;20(2):72-82

 

Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP.
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
Int J Cancer 2014 Jun 15;134(12):2829-40

 

Klein JM, Henke A, Sauer M, Bessler M, Reiners KS, Engert A, Hansen HP, von Strandmann EP.
The histone deacetylase inhibitor LBH589 (panobinostat) modulated the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
PLoS One 2013 Nov 21;8(11):e79502

 

Lam RA, Chwee JY, Le Bert N, Sauer M, Pogge von Strandman E, Gasser S.
Regulation of self-ligands for activating natural killer cell receptors.
Ann Med 2013 Jun;45(4):384-94

 

Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E.
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Blood 2013 May2;121(18):3658-65

 

Ouyang J, Plütschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA.
Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma.
Blood 2013 Apr 25;121(17):3431-3

 

Sauer M, Plütschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S, Engert A, von Strandmann EP.
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
Am J Hematol. 2013 Feb;88(2):113-5. doi: 10.1002/ajh.23361. Epub 2012 Dec 8.

 

Simhadri VL, Hansen HP, Simhadri VR, Reiners KS, Bessler M, Engert A, von Strandmann EP.
A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells.
Biol Chem. 2012 Jan;393(1-2):101-6. doi: 10.1515/BC-2011-213.

 

Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Mol Cancer Ther. 2011 Jun;10(6):1036-45. doi: 10.1158/1535-7163.MCT-10-1093. Epub 2011 Apr 27.

 

Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP.
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11.

 

Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E.
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function
PLoS One 2008;3(10):33377

 

Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A.
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and angages the NKp30 receptor on natural killer cells.
Immunity 2007 Dec;27(6):965-74